MedTrace Logo

Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer

NCT06889623 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-03-21

No results posted yet for this study

Summary

Residual tumors after transurethral resection of bladder tumors (TURBT) range from 17-70%, and floating tumor cells from traditional segmental resection may lead to recurrence if they re-implant in the bladder wall. Immediate systemic chemotherapy post-surgery aims to eliminate microlesions promptly and minimize recurrence risk, yet its safety and efficacy require further exploration. This prospective, single-arm study delves into evaluating the efficacy and safety of immediate postoperative systemic chemotherapy in patients with suspected high-risk non-muscle-invasive bladder cancer.

Conditions

Interventions

PROCEDURE

Immediate postoperative chemotherapy

Systemic chemotherapy with cisplatin/gemcitabine intravenous infusion within 24 hours after TURBT

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Shuxiong Zeng, M.D. Ph.D · Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2026-06-01
Completion
2028-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06889623 on ClinicalTrials.gov